StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report released on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 0.7 %
NASDAQ:TTNP opened at $5.24 on Monday. Titan Pharmaceuticals has a one year low of $4.24 and a one year high of $14.80. The firm’s 50 day simple moving average is $5.87 and its 200 day simple moving average is $6.30.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What Are Dividend Challengers?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Stock Market Sectors: What Are They and How Many Are There?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
